Mnuchin has a few million in this fund. I think that hurts us because enriching paulson could look bad optically, even if it the RIGHT THING TO DO!
http://www.schroders.com/getfunddocument?oid=1.9.2241573The fund was up in February, primarily from our positions in the pharma sector, which announced strong Q4
earnings and 2017 guidance. However, gains in the pharma portfolio were somewhat offset by losses in Fannie
Mae and Freddie Mac after a disappointing court verdict in one of the outstanding cases.
Our strongest performance drivers were Mylan, whose stock rallied 10% after reporting Q4 revenue up 31%
year-on-year (YoY) and adjusted EPS up 29% YoY. Full year 2016 results showed total revenue up 18% vs 2015
and adjusted EPS up 14%. Mylan also reported strong demand for drugs acquired through last year's $7.2bn
acquisition of Meda; a deal we viewed as very accretive. Shire's stock was up 8% after reporting strong 2016
earnings, up 12% YoY, along with revenue up 78% following the successful integration of the US blood disease
specialist Baxalta, which Shire acquired for $32bn.
Another strong performer was Allergan which also reported strong numbers. Q4 revenue was up 7% YoY and
overall 2016 revenue was up 15% YoY. Q4 adjusted EPS rose 16% YoY and 2017 guidance exceeded most
analyst projections. Allergan's stock rose 12% in February and 17% year to date. Despite the political noise
surrounding drug pricing, the companies we own continue to show that they are fundamentally sound, are
continuing to perform strongly and have diversified and global businesses that are not reliant on aggressive price
increases. We believe the major catalyst going forward will be the repealing and replacing of "Obamacare" which
will likely contain a deal with the industry to address the situation. Once there is more clarity and investors are able
to analyse the impact on the industry, valuations will normalise.
In the announced deals portfolio there were gains in Actelion/Johnson & Johnson, Syngenta/Chemchina,
NXP/Qualcomm and Time Warner/AT&T during February. We continue to see large deal volumes and are putting
capital to work where we find attractive risk adjusted spreads.
Fannie Mae and Freddie Mac were the largest detractors. This came after a federal appeals court upheld a ruling
that barred investors from suing to overturn the US government's 2012 decision to change the bailout terms to the
"net worth sweep" of all profits generated. Whilst the development is a setback and disappointing, we never based
our analysis on the court cases. In February, Treasury Secretary Steven Mnuchin reiterated his commitment to
housing reform and ending government ownership of the two companies. Despite the volatility, we believe there is
considerable upside to our holdings and a high probability of a resolution before the end of 2017.
Global M&A activity continued to be robust in February. Kraft Heinz made a $143bn takeover bid for Un